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- FluBlok®
- Annual Vaccine Adjustments
- Take home lessons
Baculovirus Technology Platform 
(BEVS)
BEVS Technology
“Enabling products where speed, cost and safety matter”
Baculovirus Expression Vector System (BEVS)
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FluBlok® Approval → Validaon
 Engineer baculovirus with the 
gene of interest (e.g. 
Hemagglutinin)
 Baculoviruses highly specific 
to insect cells
 Powerful promoter generates 
high yield of protein of 
interest
 Culture expression of 
insect cells in a 
fermenter
 Infect cells with 
engineered virus
 Incubate infection for ~48 
- 72 hours
 Protein forms rosettes
 Purify protein to > 90% 
into final product
 Formulate with PBS into 
vaccine
Virus  to Transfer Vector – 3  Days
Influenza Virus
RNA Extraction
RT-PCR of Full Length HA
Ligation into Transfer Plasmid
Influenza Virus




Sequencing Recombinant Baculovirus Construction
10 Plasmids per rHA





From influenza virus to 





From transfer plasmid 







Virus bank freeze down. From P3 recombinant 
baculovirus to frozen 
vials.















Insect Cell-Produced Products & 
Regulatory Approval Status
Cervarix®
First insect cell product approved by FDA
 Papillomavirus vaccine
 Approved in EU & Australia in 2007
 Approved in U.S. October 2009
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Provenge®
Second insect cell product approved
 Prostate cancer immunotherapy
 Approved May 2010





 First recombinant influenza vaccine
 First cell-based influenza vaccine in 
U.S. 
 FDA licensure imminent…
 No additional safety or efficacy studies 
required – FDA letter 01/11/10
 The pandemic solution
 Only pandemic vaccine that can be quickly 
manufactured and/or transferred to and 
manufactured in other countries
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Influenza Vaccine:
HA = Major Surface Protein
 HA (Hemagglutinin):
Coat of the influenza virus
Antibodies against HA protect against influenza
Changes in HA require annual update of vaccine
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Hemagglutinin properties
 Trimeric integral membrane protein
 Cleavage of HA with host protease into HA1 and 
HA2 needed for fusion activity
 HA1 and HA2 linked by disulfide bonds
 Contains four antigenic sites (A, B, C, and D)
 Contains many glycosylation sites
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9 studies performed 
in collaboration with 
NIAID
Safety & Immunogenicity of FluBlok
Potential Benefits (3x45µg rHA)
 Influenza rHA antigens are produced in insect cells – protein 
based vaccine with low endotoxin content
 rHA protein is highly purified and does not contain egg protein or 
other contaminants from eggs 
 Selection or adaptation of influenza virus strains that produce at  
high levels in eggs is not required =>the best genetic match 
 Cloning, expression and manufacture of FluBlok within 2 months
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 FluBlok does not require large amounts of embryonated chicken 
eggs
 Manufacturing of FluBlok does not require biocontainment
facilities
 Manufacture of rHA does not include formalin inactivation or 
organic extraction procedures
Annual Vaccine Adjustments




WHO recommended vaccine strains
H1 H3 B
2010-11 A/California/07 A/Perth/16 B/Brisbane/60
2009-10 A/Brisbane/59 A/Brisbane/10 B/Brisbane/60










At least one vaccine component strain changes 
with every new flu season
Manufacturers must respond to seasonal 
strain changes quickly
February













Universal Production Process Needed
Individual process steps:











Extraction yes infrequent pH; [detergent]
upstream
downstream
Clarification yes no DF Filter type
IEX yes often pH; [salt];
column type; 
[detergent]





Guidance for process development
•Applied to the process development for each new FluBlok component
•Developed with FDA guidance to define acceptable modifications in downstream 
process parameters within the scope of a validated process.  
• Provides assurance to FDA that:
1. any process changes are necessary and minimal.
2. process performance remains consistent season to season
• Provides guidance to process development so that:
1. development procedures and acceptance criteria  are clearly defined.
2. process changes within R00006 do not require regulatory approval
• Process changes outside of RG0006 require Change Control
SOP RG0006 guides the work flow and 
defines the downstream process design space
Challenges on Approval Path






Novel Cell Substrate 
 Baculovirus
 Daily exposure - typical serving of coleslaw contains 112 million polyhedra
(each polyhedron contains multiple baculoviruses)1
 Limited Host Range (Lepidopteran Species of Insects)
Inherent Safety ?
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 Do NOT Replicate in Mammalian Cells
 Insect Cells
 Virtually No Known Adventitious Agents Can Replicate in both Insect Cells 
and Mammalian Cells
 Arboviruses are Rare Exceptions (West Nile Encephalitis)
 Derived from Non-biting Insects – Low  Adverse Events
1Heimpel et al (1973) Environmental Entomology, vol2 (1), pp. 72.
Must screen for Nodavirus
How Might Other Products Impact 
Yours?
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Porcine circovirus DNA in rotavirus vaccine 
March 23, 2010
How Might Other Products Impact 
Yours?
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Initiate screen for all known/unknown viruses
The US Food and Drug Administration has recommended that administration of the 
Rotarix vaccine, which protects against rotavirus infection, be suspended. This 
action comes after an independent research group found that the vaccine contains 
DNA of porcine circovirus type 1. 
Pre-approval inspections 
 PAI #1  - July 2008
 17 observations (quality systems/manufacturing 
consistency)
 Response submitted August 2008
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 PAI #2 – October 2009
 7 observations
 Response submitted November 2009
Quality Systems remain area of attention
Process Validation
- Process Validation (PV)
 Challenge: Product changes annually (process; 
product stability etc.)
 Drug Substance PV now complete
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 Drug Product PV recently completed
Year H1 H3 B
2007/08 √ Failed clinical 
consistency
√
2008/09 √ √ √
2009/10 √ √ +/-
Summary: FluBlok® Regulatory Status
 FDA is committed to FluBlok approval, however, 
consistency in product quality and product safety 
needs to be ensured.
 FDA recommendation: Start the review clock at 
that time that all questions are answered.
Open issues:
 Reverse Transcriptase Investigation
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Concluding Remarks
 Key advantage = universal “plug and play” process 
 Technology may be used for the production of a broad 
range of protein-based vaccines for both human and 
veterinary use
 Technology has the potential for reduced manufacturing 
costs. 
 Existing large scale mammalian cell culture could be deployed 




 Fast Track Designation: A blessing or a curse?
 FDA product approval: “not a slam dunk”!
A recombinant influenza vaccine WILL 
become a reality thanks to support of 
30
contract HHSO100200900106C and 
perseverance of Protein Sciences 
employees.
Calvin Coolidge (30th President of the United 
States): “Nothing in the world can take the 
place of perseverance…. Persistence and 
determination alone are omnipotent.”)
